Keywords: Pfizer, Revatio, Pulmnary arterial hypertension, European approval
European Commission OKs new IV form of Pfizer’s Revatio for pulmonary arterial hypertension
Article | 6 January 2010
The European Commission has approved global drug behemoth Pfizer’s Revatio (sildenafil) solution for injection for patients who are currently prescribed oral Revatio and who are temporarily unable to take oral medicine, but are otherwise clinically and hemodynamically stable. Pfizer’s shares rose 3% to $18.75 on the news.
Revatio is the only phosphodiesterase 5 (PDE5) inhibitor with both oral and IV formulations approved in the European Union for the treatment of PAH, the company noted. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
